Educating the nurse of the future

The Morrison Government welcomes the release of the Independent Review of Nursing Education—Educating the Nurse of the Future.   The Government commissioned the review to ensure nurses are adequately equipped to meet the needs of Australia’s future health system.   Nurses are the largest single health profession in Australia, and comprise more than 40 per…

Government welcomes #YouCanTalk campaign

The Morrison Government welcomes the #YouCanTalk campaign, which encourages Australians struggling with their mental health to reach out and find support.   The awareness campaign is a collaboration between several organisations, including Beyond Blue, Everymind, headspace, Lifeline, ReachOut, RU OK?, SANE Australia, the Centre of Best Practice in Aboriginal and Torres Strait Islander Suicide Prevention,…

Red Nose and University of Queensland to share stillbirth education funding

The Morrison Government is investing $3 million through two organisations to improve community education and awareness about stillbirth.   Tragically, six babies are stillborn every day in Australia, with 2000 families affected by stillbirth every year.   Red Nose Limited and the University of Queensland, Stillbirth Centre of Research Excellence (Stillbirth CRE) will each receive…

Making Australia an international leader in medicinal cannabis

The Morrison Government is maximising the economic potential of Australia’s medicinal cannabis industry, with Major Project Status granted for the development of new facilities in South East Queensland and regional Victoria. Minister for Industry, Science and Technology Karen Andrews said the medicinal cannabis industry can boost exports and create jobs, with the potential to grow…

Psoriasis sufferers, asthmatics, UCD patients to save thousands as key medicines are added, expanded on the PBS

Australians living with psoriasis, severe asthma and urea cycle disorder are set to experience significant financial relief, with breakthrough medicines to be added and expanded on the Pharmaceutical Benefits Scheme (PBS), on December 1. Patients with moderate to severe plaque psoriasis will have access to the new psoriasis drug Skyrizi® (risankizumab). Psoriasis is a long-term…